	Application No.	Applicant(s)	
Notice of Allowability	09/929,666 Examiner		
		ANDERSON ET AL. Art Unit	
	Vickie Kim	1614	
The MAILING DATE of this communication app All claims being allowable, PROSECUTION ON THE MERITS IS herewith (or previously mailed), a Notice of Allowance (PTOL-85 NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT I of the Office or upon petition by the applicant. See 37 CFR 1.31	pears on the cover sheet was (OR REMAINS) CLOSED in the commodification is RIGHTS. This application is	th the correspondence address n this application. If not included unication will be mailed in due course. The	H IS itiative
1. This communication is responsive to <u>Feb. 02/2004</u> .			
2. The allowed claim(s) is/are 1.3.4 and 13-21.			
3. The drawings filed on are accepted by the Examin	er.		,
 4. Acknowledgment is made of a claim for foreign priority of a) All b) Some* c) None of the: 1. Certified copies of the priority documents have 2. Certified copies of the priority documents have 3. Copies of the certified copies of the priority documents have International Bureau (PCT Rule 17.2(a)). * Certified copies not received: 	ve been received. ve been received in Application	on No	he
Applicant has THREE MONTHS FROM THE "MAILING DATE noted below. Failure to timely comply will result in ABANDON THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		e a reply complying with the requirements	S
5. A SUBSTITUTE OATH OR DECLARATION must be submits INFORMAL PATENT APPLICATION (PTO-152) which girls.			=
6. CORRECTED DRAWINGS (as "replacement sheets") mi	ust be submitted.		
(a) including changes required by the Notice of Draftspe	rson's Patent Drawing Revie	w (PTO-948) attached	
1) 🗌 hereto or 2) 🔲 to Paper No./Mail Date	_•	· ·	
(b) including changes required by the attached Examine Paper No./Mail Date	r's Amendment / Comment o	r in the Office action of	
Identifying indicia such as the application number (see 37 CFR each sheet. Replacement sheet(s) should be labeled as such in	1.84(c)) should be written on the header according to 37 C	he drawings in the front (not the back) of FR 1.121(d).	
7. DEPOSIT OF and/or INFORMATION about the dep attached Examiner's comment regarding REQUIREMENT			
Attachment(c)			
Attachment(s) 1. Notice of References Cited (PTO-892)	5. Notice of Ir	formal Patent Application (PTO-152)	
2. Notice of Draftperson's Patent Drawing Review (PTO-948)	6. Interview S	ummary (PTO-413), /Mail Date	
3. Information Disclosure Statements (PTO-1449 or PTO/SB Paper No./Mail Date		Amendment/Comment	
Examiner's Comment Regarding Requirement for Deposit of Biological Material	8. ☐ Examiner's 9. ☐ Other	Statement of Reasons for Allowance	
		Vickie Kim Primary Examiner Art Unit: 1614	

Application/Control Number: 09/929,666

Art Unit: 1614

EXAMINER'S AMENDMENT

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Patel, Sandip on 3/10/04.

- 2. The application has been amended as follows:
 - a. Replace the claim 1 with newer amended version as following:
 - --- Claim 1 (currently amended): A method of treating or suppressing the symptoms of addictive disorders selected from the group consisting of alcohol addiction, tobacco addiction, nicotine addiction, and intoxication and inhalation disorders associated with alcohol, tobacco and nicotine addiction, said method comprising the step of administering to a patient in need of treatment a therapeutically effective, nontoxic amount of an active agent wherein the active agent is a heterocyclic amine of the formula:

R¹ R²

or a pharmaceutically acceptable salt thereof, wherein:

Amend 3/18/04 R^1 , R^2 and R^3 are each independtly hydrogen, C_{1-6} alkyl, C_{3-5} alkenyl, C_{3-5} alkynyl, C_{3-7} cycloalkyl, C_{4-10} cycloalkyl- or phenyl- substituted C_{1-6} alkyl, or R^1 and R^2 are joined to form a C_{3-7} cyclic amine which can contain additional heteroatoms and/or unsaturation;

n is 0 or 1;

X is hydrogen, C_{1-6} alkyl, halogen, alkoxy, cyano, carboxamide, carboxyl, or carboalkoxyl;

A is CH, CH₂, CH-halogen, CHCH₃, C=O, C-SCH₃, C=NH, C-NH₂, C-NHCH₃, C-NHCOOCH₃, C-NHCN, SO₂, or N;

B is CH₂, CH, CH-halogen, C=O, N, NH, N-CH₃, or O;

D is CH₂, CH, CH-halogen, C=O, O, N, NH, N-CH₃; and pharmaceutically acceptable derivatives or salts of said active agent. ---

- b. In claim 17, lines 2-3, delete the phrase [selected from the group consisting of a heterocyclic amine, a phenylazacycloalkane, and a cabergoline] right before "administered".
- c. In claim 18, lines 2-3, delete the phrase [selected from the group consisting of a heterocyclic amine, a phenylazacycloalkane, and a cabergoline] right before "administered".

7100

3/18/1

Conclusion

Application/Control Number: 09/929,666 Page 4

Art Unit: 1614

3. All the pending claims are allowed.

4. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 571-272-0579(fax: 571-273-0579). The examiner can normally be reached on Tuesday-Friday. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Marianne Seidel can be reached on 571-272-0584. The fax phone numbers for the organization where this application or proceeding is assigned are 703-872-9306 for regular communications and 703-746-3165 for After Final communications. Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 571-272-1600.

VICKIE KIM PRIMARY EXAMINER

Vickie Kim March 20, 2004 Art unit 1614